Vaccines for the treatment of non-small cell lung cancer: A renewed anticancer strategy

Oncologist

Volumn 14, Issue 9, 2009, Pages 909-920

  Gridelli, Cesare ^a   Rossi, Antonio ^a   Maione, Paolo ^a   Ferrara, Marianna Luciana ^b   Castaldo, Vincenzo ^a   Sacco, Paola Claudia ^a  

^a S G MOSCATI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

L BLP25; MAGE A3; NSCLC; Vaccine therapy

Indexed keywords

BCG VACCINE; BELAGENPUMATUCEL L; CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; GEMCITABINE; LUCANIX; MELANOMA ANTIGEN 3; MITOMYCIN; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VINBLASTINE;

ANTIGEN SPECIFICITY; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER STAGING; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MYCOBACTERIUM VACCAE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY, ACTIVE; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 70349416505     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0017     Document Type: Review

References (59)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252.
2. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970;169:1042-1049.
3. Lechler R, Chai JG, Marelli-Berg F et al. The contribution of T-cell anergy to peripheral T-cell tolerance. Immunology 2001;103:262-269. (Pubitemid 32626175)
4. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-258.
5. Russel JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002;20:323-370.
6. Szabo SJ, Sullivan BM, Peng SL et al. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 2003;21:713-758. (Pubitemid 37174546)
7. Farber DL. T cell memory: Heterogeneity and mechanisms. Clin Immunol 2000;95:173-181.
8. Ribas A, Butterfield LH, Glaspy JA et al. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003;21:2415-2432. (Pubitemid 46621880)
9. Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 2004;363:594-599. (Pubitemid 38264176)
10. Uyl-de Groot CA, Vermorken JB, HannaMGJr et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: A prospective study of medical and economic benefits. Vaccine 2005;23:2379-2387.
11. Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: Current status and future directions. Vaccine 2007;25(suppl 2):B4-B16. (Pubitemid 47488552)
12. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216.
13. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031-1039.
14. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005;11(4 suppl):S63-S68. (Pubitemid 40562305)
15. Peat N, Gendler SJ, Lalani N et al. Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res 1992;52:1954 -1960.
16. Vlad AM, Kettel JC, Alajez NM et al. MUC1 immunobiology: From discovery to clinical applications. Adv Immunol 2004;82:249-293.
17. Rochlitz C, Figlin R, Squiban P et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 2003;5:690-699. (Pubitemid 40309707)
18. Kontani K, Taguchi O, Ozaki Y et al. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med 2003;12:493-502.
19. + T cell responses against cancer-associated MUC1 peptide epitome. Int Immunol 1998;10:1907-1916.
20. North S, Butts C. Vaccination with BLP25 liposome vaccine to treat nonsmall cell lung cancer and prostate cancers. Expert Rev Vaccines 2005;4: 249-257. (Pubitemid 40978689)
21. Palmer M, Parker J, Modi S et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 2001;3:49 -57; discussion 58. (Pubitemid 32904315)
22. Butts C, Murray N, Maksymiuk A et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23:6674-6681. (Pubitemid 46190262)
23. Butts C, Maksymiuk A, Goss G et al. A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): Updated survival analysis [abstract B1-01]. J Thorac Oncol 2007;2(suppl. 4):S332-S333.
24. Malykh YN, Schauer R, Shaw L. N-Glycolylneuraminic acid in human tumours. Biochimie 2001;83:623-634.
25. Ramlau R, Quoix E, Rolski J et al. A phase II study of Tg4010 (Mva-Muc1- Il2) in association with chemotherapy in patients with stage III/IV nonsmall cell lung cancer. J Thorac Oncol 2008;3:735-744.
26. Ramlau R, Westeel V, Papai Z et al. Randomized phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) [abstract 8023]. J Clin Oncol 2008;26(suppl 15):429s.
27. Drugs.com. Transgene's Therapeutic Vaccine TG4010: Promising Additional Clinical Data in Non-Small Cell Lung Cancer Phase IIb Trial. Available at http://www.drugs.com/clinical-trials/transgene-s-therapeuticvaccine- tg4010-promising-additional-clinical-data-non-small-cell-lung- 5528.html, accessed June 10, 2009.
28. Vázquez AM, Gabri MR, Hernández AM et al. Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides. Oncol Rep 2000;7:751-756.
29. Chen K, Huang J, GongWet al. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 2007;7:1271-1285.
30. Alfonso S, Diaz RM, de la Torre A et al. 1E10 anti-idiotype vaccine in nonsmall cell lung cancer: Experience in stage IIIb/IV patients. Cancer Biol Ther 2007;6:1847-1852. (Pubitemid 351590395)
31. Gupta K, Cooper C. A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R D 2008;9:137-145. (Pubitemid 351651997)
32. Manegold C, Gravenor D, Woytowitz D et al. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advancedstage non-small-cell lung cancer J Clin Oncol 2008;26:3979-3986.
33. Hirsh V, Boyer M, Rosell R et al. Randomized phase III trial of paclitaxel/ carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC) [abstract 8016]. J Clin Oncol 2008; 26(suppl 15):428s.
34. Manegold C, Thatcher N, Benner RJ et al. Randomized phase III trial of gemcitabine/cisplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC) [abstract 8017]. J Clin Oncol 2008;26(suppl 15):428s.
35. Salomon DS, Brandt R, Ciardiello F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
36. González G, Crombet T, Catalá M et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial. Ann Oncol 1998;9:431-435. (Pubitemid 28273037)
37. Gonzalez G, Crombet T, Torres F et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 2003;14: 461-466. (Pubitemid 36367426)
38. Ramos TC, Vinageras EN, Ferrer MC et al. Treatment of NSCLC patients with an EGF-based cancer vaccine: Report of a phase I trial. Cancer Biol Ther 2006;5:145-149.
39. González G, Crombet T, Neninger E et al. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: Analysis of pooled data from three clinical trials. Hum Vaccin 2007;3:8-13. (Pubitemid 46273001)
40. García B, Neninger E, de la Torre A et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by antiepidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 2008;14:840-846. (Pubitemid 351231168)
41. Neninger Vinageras E, de la Torre A, Osorio Rodríquez M et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008;26:1452-1458.
42. Sienel W, Varwerk C, Linder A et al. Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: Results of a multi-center study. Eur J Cardiothorac Surg 2004;25:131-134. (Pubitemid 38019071)
43. Gaugler B, van den Eynde B, van Der Bruggen P et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179:921-930. (Pubitemid 24065650)
44. Vansteenkiste J, Zielinski M, Linder A et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC) [abstract 7554]. J Clin Oncol 2007;25(suppl 18):398s.
45. Vansteenkiste J, Zielinski M, Dahabreh IJ et al. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II nonsmall cell lung cancer (NSCLC) [abstract 7501]. J Clin Oncol 2008; 26(suppl 15):397s.
46. Hoover HC Jr, Surdyke M, Dangel RB et al. Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guérin vaccine. Cancer Res 1984;44:1671-1676. (Pubitemid 14125862)
47. Schulof RS, Mai D, Nelson MA et al. Active specific immunotherapy with an autologous tumor cell vaccine in patients with resected non-small cell lung cancer. Mol Biother 1988;1:30-36.
48. Grange JM, Bottasso O, Stanford CA et al. The use of mycobacterial adjuvant- based agents for immunotherapy of cancer. Vaccine 2008;26:4984-4990.
49. O'Brien ME, Saini A, Smith IE et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 2000;83:853-857. (Pubitemid 30707618)
50. O'Brien ME, Anderson H, Kaukel E et al. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: Phase III results. Ann Oncol 2004;15:906-914. (Pubitemid 39004346)
51. Stanford JL, Stanford CA, O'Brien ME et al. Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer 2008;44:224-227.
52. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993;90:3539-3543. (Pubitemid 23111402)
53. Nemunaitis J, Sterman D, Jablons D et al. Granulocyte-macrophage colony- stimulating factor gene-modified autologous tumor vaccines in nonsmall- cell lung cancer. J Natl Cancer Inst 2004;96:326-331. (Pubitemid 38256277)
54. Borrello I, Sotomayor EM, Cooke S et al. A universal granulocyte- macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther 1999;10:1983-1991. (Pubitemid 29387912)
55. Nemunaitis J, Jahan T, Ross H et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 2006;13:555-562. (Pubitemid 43756243)
56. Kong F, Jirtle RL, Huang DH et al. Plasma transforming growth factor-β1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 1999;86:1712-1719. (Pubitemid 29513039)
57. Nemunaitis J, Dillman RO, Schwarzenberger PO et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense genemodified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006;24:4721-4730. (Pubitemid 46630936)
58. Soon YY, Stockler MR, Askie LM et al. Duration of chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis of randomized trials. J Clin Oncol 2009;27:3277-3283.
59. Garland SM, Hernandez-Avila M, WheelerCMet al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.N Engl J Med 2007;356:1928-1943.